BioSenic reports half year 2023 results itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces its business update for the first quarter, ended 31 March 2023. Key highlights. Strengthening of Executive Committee and Board of Directors with the .
REGULATED INFORMATION ALLOB Phase IIb topline results foreseen in July/August 2023Ongoing discussions for key partnerships with lead clinical assets Mont-Saint-Guibert, Belgium, May 22nd,. | May 22, 2023
REGULATED INFORMATION Mont-Saint-Guibert, Belgium, January 27, 2023, 7am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company.